Multiple Myeloma CPG Mini Module - Antibody-Drug Conjugates

The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, three on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.   

In this module, Dr. Jesus Berdeja, MD - Sarah Cannon Research Institute, Dr. Nina Shah, MD University of California - San Francisco, and Dr. Yi Lin, MD PhD, Mayo Clinic, describe the use of antibody-drug conjugates, specifically belantamab mafodotin, in multiple myeloma.  A particular focus is placed on the ocular toxicities of this agent and ways to manage patients on this therapy as a result.

Target Audience 

Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants and radiologists. 

SITC Online Education Disclaimer 

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

The Practical Management Pearls and Case Studies Webinars and CPG Mini Modules (previously referred to as the "Ten Minute Modules") are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 9/15/2021). CE credits are not available for these webinars.
 
The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts.